LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Aandelen Lijst・Quanterix Corp

Quanterix Corp

Gesloten

SectorGezondheidszorg

3.5 -0.57

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.29

Max

3.54

Belangrijke statistieken
By Trading Economics
Inkomsten	5.6M -18M
Verkoop	-7.4M 36M
EPS	0.16
Winstmarge	-48.17
Werknemers	450
EBITDA	1.5M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+14.29% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	6.3M 165M
Vorige openingsprijs	4.07
Vorige sluitingsprijs	3.5

Nieuwssentiment

By Acuity

63%

37%

279 / 344 Rangschikking in Healthcare

Quanterix Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2026, 20:30 UTC

Winsten

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 jun 2026, 23:58 UTC

Marktinformatie

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 jun 2026, 23:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 jun 2026, 23:41 UTC

Marktinformatie

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 jun 2026, 23:01 UTC

Acquisities, Fusies, Overnames

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 jun 2026, 23:01 UTC

Acquisities, Fusies, Overnames

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 jun 2026, 23:00 UTC

Acquisities, Fusies, Overnames

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 jun 2026, 22:57 UTC

Marktinformatie

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 jun 2026, 22:50 UTC

Marktinformatie

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 jun 2026, 21:07 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 jun 2026, 21:07 UTC

Marktinformatie

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 jun 2026, 21:00 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

2 jun 2026, 20:46 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:38 UTC

Winsten

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 jun 2026, 20:21 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:12 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Product Rev $594M

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Loss $177M >PANW

Peer Vergelijking

Prijswijziging

Quanterix Corp Prognose

Koersdoel

By TipRanks

14.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 14.29%

Hoogste 4 USD

Laagste 4 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Quanterix Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Quanterix Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

279 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.